The TNF/IL-23/IL-17 axis - head-to-head trials comparing different biologics in psoriasis treatment

Scandinavian Journal of Immunology
Lisa Lynn Ten BergenSilke Appel

Abstract

Psoriasis is a T cell-mediated disease with autoimmune characteristics modulated by genetic susceptibility along with environmental triggers. Inflammatory pathways marked with excessive production of cytokines IL-12 and IL-23, drive differentiation of pathogenic T cell responses resulting in TNF and IL-17 production. These cytokines are an integral part of the TNF/IL-23/IL-17 axis, which is responsible for maintaining inflammation in psoriatic skin. Our improved understanding of the immunopathogenesis led to the development of biological drugs in the treatment of moderate-to-severe disease. Biologics have revolutionized the management of psoriasis, highlighting the central role of TNF/IL-23/IL-17 axis in the physiopathology of the disease. Still, psoriasis usually requires long-term treatment, aiming to fully remove psoriatic lesions without experiencing adverse events. In this review, we discuss the recent findings of all 27 available head-to-head trials investigating the efficacy and safety of systemic and biologic therapies in moderate-to-severe psoriasis vulgaris, as it is thought to provide more useful knowledge than placebo intervention alone. According to our evaluation, inhibitors that specifically target IL-23 or IL-17...Continue Reading

References

Apr 7, 1990·BMJ : British Medical Journal·D J EedyF G Jones
Dec 12, 1986·JAMA : the Journal of the American Medical Association·C N EllisT M Annesley
Mar 1, 1995·Clinics in Dermatology·I A McKay, I M Leigh
Sep 27, 1994·Proceedings of the National Academy of Sciences of the United States of America·J C ChangD J Carlo
Jul 28, 2001·The New England Journal of Medicine·C N EllisUNKNOWN Alefacept Clinical Study Group
Nov 25, 2003·The New England Journal of Medicine·Craig L LeonardiUNKNOWN Etanercept Psoriasis Study Group
Dec 17, 2003·Archives of Dermatology·Alice B GottliebRalph Zitnik
Dec 18, 2003·Clinical and Experimental Immunology·J E GudjonssonH Valdimarsson
Sep 25, 2004·Journal of the American Academy of Dermatology·Alice B GottliebAlan Menter
Feb 15, 2005·Annals of the Rheumatic Diseases·R G B LangleyC E M Griffiths
Jul 30, 2005·Arthritis and Rheumatism·P P SfikakisA Stratigos
Oct 16, 2007·Journal of the American Academy of Dermatology·Alan MenterKim Papp
Nov 28, 2007·The Journal of Experimental Medicine·Lisa C ZabaJames G Krueger
Sep 20, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Ilona KryczekWeiping Zou
Jan 27, 2009·Nature Genetics·Rajan P NairUNKNOWN Collaborative Association Study of Psoriasis
Dec 26, 2009·Journal of Autoimmunity·Vinod Chandran, Siba P Raychaudhuri
Jan 8, 2010·The Journal of Investigative Dermatology·Yuangang LiuMolly F Kulesz-Martin
Jan 15, 2010·The New England Journal of Medicine·Christopher E M GriffithsUNKNOWN ACCEPT Study Group
Mar 26, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Karline GuilloteauFranck Morel
Oct 19, 2010·Nature Genetics·Philip E StuartJames T Elder
Oct 19, 2010·Nature Genetics·UNKNOWN Genetic Analysis of Psoriasis Consortium & the Wellcome Trust Case Control Consortium 2Richard C Trembath
Nov 19, 2010·The Journal of Investigative Dermatology·Andrea ChiricozziJames G Krueger
Sep 2, 2011·The Journal of Investigative Dermatology·Yijun CarrierQuintus G Medley
Oct 14, 2011·Nature Immunology·Vladimir Ramirez-CarrozziRajita Pappu
Mar 30, 2012·The New England Journal of Medicine·Kim A PappScott Baumgartner
Mar 30, 2012·The New England Journal of Medicine·Craig LeonardiSubhashis Banerjee
Sep 28, 2012·The Journal of Investigative Dermatology·Rosa ParisiUNKNOWN Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team
Jan 3, 2013·Journal of the European Academy of Dermatology and Venereology : JEADV·E MahéUNKNOWN GEM Resopso
Apr 5, 2013·The British Journal of Dermatology·E A DowlatshahiT Nijsten
Sep 27, 2013·Science Translational Medicine·Kerstin WolkRobert Sabat
Oct 16, 2013·Journal of the American Academy of Dermatology·Anne MasonGordon Dooley
Mar 25, 2014·Annual Review of Immunology·Michelle A LowesJames G Krueger

❮ Previous
Next ❯

Citations

May 1, 2021·Journal of Personalized Medicine·Cristina Membrive JiménezAlberto Jiménez Morales

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Related Papers

Giornale Italiano Di Dermatologia E Venereologia : Organo Ufficiale, Società Italiana Di Dermatologia E Sifilografia
Kazuhisa FurueMasutaka Furue
Nature Reviews. Drug Discovery
Daniel B DubinRonald Ellis
Journal of Drugs in Dermatology : JDD
Leon H Kircik, Mercedes E Gonzalez
© 2021 Meta ULC. All rights reserved